| Table 2. Arguments for prions being composed largely,
if not entirely, of PrPSc molecules and devoid of
nucleic acid |
|
| 1 |
PrPSc and scrapie
infectivity copurify when biochemical and immunologic procedures
are used. |
| 2 |
The unusual properties of PrPSc
mimic those of prions. Many different procedures that modify
or hydrolyze PrPSc inactivate prions. |
| 3 |
Levels of PrPSc
are directly proportional to prion titers. Nondenatured PrPSc
has not been separated from scrapie infectivity. |
| 4 |
No evidence exists for a virus-like particle
or a nucleic acid genome. |
| 5 |
Accumulation of PrPSc
is invariably associated with the pathology of prion diseases,
including PrP amyloid plaques that are pathognomonic. |
| 6 |
PrP gene mutations are genetically linked
to inherited prion disease and cause formation of PrPSc. |
| 7 |
Overexpression of PrPC
increases the rate of PrPSc formation, which shortens
the incubation time. Knock out of the PrP gene eliminates the
substrate necessary for PrPSc formation and prevents
both prion disease and prion replication. |
| 8 |
Species variations in the PrP sequence are
responsible, at least in part, for the species barrier that is
found when prions are passaged from one host to another. |
| 9 |
PrPSc preferentially
binds to homologous PrPC, resulting in formation of
nascent PrPSc and prion infectivity. |
| 10 |
Chimeric and partially deleted PrP genes
change susceptibility to prions from different species and support
production of artificial prions with novel properties that are
not found in nature. |
| 11 |
Prion diversity is enciphered
within the conformation of PrPSc. Strains can be generated
by passage through hosts with different PrP genes. Prion strains
are maintained by PrPC/PrPSc interactions. |
| 12 |
Human prions from fCJD(E200K) and FFI patients
impart different properties to chimeric MHu2M PrP in transgenic
mice, which provides a mechanism for strain propagation. |